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ABSTRACT 
Hemoglobin (Hb), an oxygen-carrying protein, has an α2β2 tetrameric structure that 
dissociates reversibly into two αβ dimers (α2β2 ⇄ 2αβ). We synthesized a cyclic Hb-ring 
monomer with two β subunits bound through a 10 kDa PEG chain. The monomer induced ring-
opening polymerization to produce a supramolecular polymer via inter-subunit interaction of αβ 
dimers of an Hb molecule at the PEG terminals. Both the ring-closed monomer and the ring-
opened supramolecular polymer were then fixed covalently by intramolecular crosslinking of 
two β subunits. Quantification of fixed products at various monomer concentrations revealed the 
equilibrium constant (K), a ratio of propagation and depropagation rate constants, as 5.68 mM−1. 
The average degree of polymerization (DP����) increased proportionally, concomitantly with the 
initial monomer concentration. Hb polymer with DP���� = 13.2 (Mn = ca. 1 MDa) was obtained by 
crosslinking at 2.33 mM. Our novel strategy of ring-opening polymerization of Hb will 
eventually realize a highly aligned and efficiently polymerized Hb for creating artificial oxygen 
carriers for a clinical use. 
 
KEYWORDS: supramolecular chemistry, cyclic protein monomer, PEG modification, blood 





A supramolecular polymer is a class of polymeric arrays of monomers bound thorough 
non-covalent bonding such as hydrogen bonds, metal coordination bonds, host–guest 
interactions, and aromatic donor–acceptor interactions.1 Specific interactions between proteins 
such as coiled-coil interaction, heme–heme pocket interaction, and hapten–antibody complex 
formation are also targeted to produce supramolecular protein polymers.2 We regard such 
supramolecular polymerization techniques as applicable to create a hemoglobin (Hb) polymer 
that will eventually be available as an artificial oxygen carrier for clinical use. 
Hb is an oxygen-carrying protein compartmentalized in red blood cells (RBC). Many 
attempts have been undertaken to create artificial oxygen carriers using isolated Hb from RBC. 
Such Hb-based oxygen carriers (HBOCs) present several important benefits: they are pathogen 
free, have no blood type, and have longer shelf life than RBC. For those reasons, they are 
anticipated for use as RBC substitutes.3 Nevertheless, some difficulties arise when the isolated 
Hb molecules are injected into circulation. An Hb molecule, which consists of α2β2 tetramer, 
dissociates into two αβ subunits. The dimers are caught by haptoglobin and are removed from 
circulation immediately, thereby causing nephrotoxicity or adverse cardiovascular effects.4 
Severe adverse effects such as vasoconstriction, hypertension, and oxidative stress are ascribed 
to the scavenging of the endothelium-derived relaxing factor, nitric oxide, by extravasation of 
small Hb molecules through the endothelial layer.5 
Various approaches for chemical modification of Hb have been developed to resolve 
these difficulties. For instance, intramolecular αα- or ββ-crosslinked Hb6−8 inhibits dissociation 
of α2β2 tetrameric structure while preventing biomolecular association with haptoglobin.9 Non-
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immunogenic polymers such as polyethylene glycol (PEG)10,11 or albumin12 are conjugated to Hb 
molecules to lower antigenicity by surface covering. 
The intermolecular conjugation of multiple Hbs represents a promising approach to 
prevent extravasation by enlarging the particle size of HBOCs. Several kinds of oligomerized or 
polymerized Hbs are produced by crosslinking Hbs with glutaraldehyde,13 polyamide linker,14,15 
oligo- or poly-saccharides,16,17 site-specific dimerizing reagents,18,19 and bi-functional PEGs.20 In 
fact, glutaraldehyde-polymerized Hbs (poly-Hbs) entered clinical trials for patients, although 
some have already been discontinued.21 These poly-Hbs contain monomeric Hb or low 
molecular weight Hb oligomers. Adverse effects of vasoconstriction are expected to result from 
permeation of such small molecules across endothelial layer and extravasation.22 Therefore, 
development for realizing highly efficient polymerization of Hbs is now sought to improve 
existing poly-Hbs. Polymerized Hbs with molecular weight of tens of MDa was produced by 
zero-linking of Hb molecules.23 Other approaches to creating HBOCs without using chemical 
modification have also been developed. Encapsulation of Hb molecules in polymer membranes24 
or in liposomes25 is conducted as a shield against toxicity of Hb molecules. 
For this work, we developed an efficient polymerization procedure for creating Hb 
polymer using a novel approach: ring-opening polymerization. We earlier evaluated the 
exchange reaction of αβ subunits between two-PEG-chains conjugated Hb and native Hb in a 
physiological condition.26 Based on results of that work, we designed an intramolecularly PEG-
bridged Hb as a cyclic Hb-ring monomer (Hb-rPEG, Figure 1). For this study, Hb-rPEG was 
synthesized by reacting native Hb with a bi-functional PEG with maleimide terminals (mal2-
PEG) known to conjugate selectively to β93Cys.27 During the intermolecular subunit exchange 
of αβ dimers, Hb-rPEG is expected to induce ring-opening polymerization to produce 
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dibromosalicyl) fumarate (DBBF) to produce a corresponding fixed monomer and a polymer: 
XL-Hb-rPEG and XL-poly(Hb−PEG). The X-ray crystal structure (PDB ID: 1BIJ) of the Hb 
crosslinked by DBBF (XLHb) is shown, particularly displaying the binding sites for maleimide 
(β93Cys) and for DBBF (β82Lys).28  
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2. MATERIALS AND METHODS 
2.1. Materials 
Human Hb used for this work was purified from RBCs provided by the Japanese Red 
Cross. As reported elsewhere in the literature,29 a highly purified carbonyl Hb (native Hb) 
solution was obtained through pasteurization and nanofiltration. DBBF crosslinked Hb (XLHb) 
was also prepared as reported in the literature.26,30 The Hb derivative concentrations were 
determined using Hemoglobin B-test Wako (Fujifilm Wako Pure Chemical Corp.).  
Sodium chloride, potassium chloride, disodium hydrogen phosphate (Na2HPO4), 
potassium dihydrogen phosphate (KH2PO4), polyethylene glycol 20,000 (20 kDa PEG), 
ammonium sulfate, Tris(hydroxymethyl) aminomethane (Tris), sucrose, sodium dodecyl sulfate 
(SDS), 2-mercaptoethanol, bromophenol blue, and Coomassie brilliant blue (Quick CBB) were 
purchased from Fujifilm Wako Pure Chemical Corp. (Osaka, Japan). Saline (Otsuka normal 
saline) was purchased from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). Albumin (25% 
human serum albumin) was purchased from Japan Blood Products Organization (Tokyo, Japan). 
Bi-functional maleimide PEG, mal2-PEG (Figure 1; SUNBRIGHT DE-100MA, Lot M153536, 
Mn 10456, Mw/Mn = 1.02, substitution 90.6%) was purchased from NOF Corp. (Tokyo, Japan). 
Bis-(3,5-dibromosalicyl) fumarate (Figure 1; DBBF) was purchased from Abcam plc. 
(Cambridge, U.K.). 
 
2.2. Synthesis of Hb-ring monomer (Hb-rPEG) 
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To a 31.0 mL of native Hb solution (1.55 mM, 10.0 g/dL, 48.0 μmol) in phosphate-
buffered saline (PBS, pH 7.4, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM 
KH2PO4) was added 0.83 molar equivalent of powdered mal2-PEG (418.2 mg, 40.0 μmol, Mn 
10456), followed by stirring under a CO atmosphere for 20 h at 4 °C. Crude Hb-rPEG was 
purified five times by salting out using 3 M ammonium sulfate aqueous solution for native Hb 
removal. After the precipitate was dissolved in PBS, the solution was dialyzed for 20 h using a 
dialysis membrane (Size 27; Fujifilm Wako Chemicals U.S.A. Corp., Richmond, U.S.A.) against 
400 mL PBS to remove ammonium sulfate. Then the solution was dialyzed for 4 h against a 
highly concentrated 20 kDa PEG aqueous solution. In this procedure, water and other small 
molecules were withdrawn for concentration. Finally, it was dialyzed against 400 mL PBS for 2 
h. Consequently, 10.84 mL Hb-rPEG solution was obtained (2.84 mM, [Hb] = 18.3 g/dL, yield 
76.7%). 
 
2.3. DBBF crosslinking of Hb-rPEG at different concentrations 
Concentrated Hb-rPEG solutions (2.84 mM, [Hb] = 18.3 g/dL) with 13.2–52.9 μL 
volume were diluted with PBS to prepare solutions having seven respective concentrations. Each 
solution was stirred for 8 h at 4 °C. Subsequently, 2.0 molar equivalent DBBF was added as a 
suspension (10 or 20 mg/mL suspension in PBS). The final Hb concentrations were then adjusted 
to 0.04, 0.08, 0.16, 0.31, 0.62, 1.55, and 2.33 mM ([Hb] = 0.25, 0.5, 1.0, 2.0, 4.0, 10.0, and 15.0 
g/dL). The mixtures were then stirred for 3 h at room temperature. Each solution was diluted 




2.4. Synthesis of XL-poly(Hb−PEG) 
To a 5 mL PBS solution of Hb-rPEG (2.33 mM, [Hb] = 15.0 g/dL, 11.6 μmol) was added 
1.6 molar equivalent of powdered DBBF (12.50 mg, 18.6 μmol). It was then stirred under a CO 
atmosphere for 3 h at room temperature. The reaction mixture was filtered through a syringe-
driven membrane filter (DISMIC-25CS 0.45 μm cellulose acetate filter; Toyo Roshi Kaisha Ltd., 
Tokyo, Japan). A higher molecular weight component was fractionated using size exclusion 
chromatography (2 cm diameter and 30 cm height open column, Sepharose CL4B; Sigma-
Aldrich Corp., St. Louis, U.S.A.). The fraction containing a higher molecular weight component 
was concentrated using a centrifugal filter unit (Amicon Ultra-15, 100 kDa cutoff; Merck 
Millipore, Merck KGaA, U.S.A.) to obtain 0.87 mL of XL-poly(Hb−PEG) solution (0.58 mM, 
[Hb] = 3.74 g/dL, yield 4.3%). 
 
2.5. Exchange of αβ subunits between Hb-rPEG and native Hb, and subsequent DBBF 
crosslinking 
After Hb-rPEG was mixed with native Hb in 0.10 mL PBS, it was stirred for 24 h at 4 °C. 
Then, 2.0 molar equivalent DBBF to total Hb was reacted. The final concentration of Hb-rPEG 
was fixed to 1.55 mM ([Hb] = 10.0 g/dL). That of native Hb was adjusted to 1.55, 0.62, and 0.31 
mM (10.0, 4.0, and 2.0 g/dL). For SEC analysis, each resulting solution was diluted 50 times 
with PBS to adjust the Hb-rPEG concentration to 0.031 mM ([Hb] = 0.20 g/dL). For comparison, 
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1.55 mM Hb-rPEG solution ([Hb] = 10.0 g/dL) without adding native Hb was also reacted with 
DBBF. 
 
2.6. Intermolecular conjugation of XLHbs by mal2-PEG 
Preformed 0.10 mL XLHb solution (3.78 mM, 24.4 g/dL, 0.38 μmol) was mixed with 
0.10 mL mal2-PEG (Mn 10456) solution in PBS and was stirred for 24 h at 4 °C. The molar ratios 
of XLHb to mal2-PEG were adjusted to 1.0 and 0.50. Each reaction mixture contained 
conjugated XLHbs through PEG chains (polymerized XLHb (poly(XLHb)) and/or oligomerized 
XLHb (oligo(XLHb)). Oligo(XLHb) was fractionated using a high-performance liquid 
chromatography system (HPLC, Chromaster; Hitachi High-Technologies Corp., Tokyo, Japan) 
equipped with a SEC column (Shodex Protein KW-804; Showa Denko K.K., Tokyo, Japan) to 
obtain solutions of a dimer, a trimer, a tetramer, and a pentamer. 
The dumbbell-type XLHb dimer, XLHb−PEG−XLHb, was synthesized for use as a 
reference. To a 240 mL of vigorously stirred XLHb solution (1.00 mM, 6.45 g/dL, 0.24 mmol) in 
PBS was added 0.083 molar equivalent mal2-PEG solution (Mn 10456, 209.12 mg, 0.0200 mmol 
in 4.2 mL PBS) dropwise. Then, the mixture was stirred for 2 h under a CO atmosphere at room 
temperature, and subsequently at 4 °C for 10 h. Excess XLHb was removed four times by salting 
out using 3 M ammonium sulfate solution. After the precipitate was dissolved in PBS, the 
solution was dialyzed for 24 h using a dialysis membrane (Size 27; Fujifilm Wako Chemicals 
U.S.A. Corp.) against 400 mL saline to remove ammonium sulfate. Then it was dialyzed for 4 h 
against a highly concentrated 20 kDa PEG aqueous solution. Finally, it was dialyzed against 400 
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mL PBS for 2 h. Consequently, 8.71 mL XLHb−PEG−XLHb solution was obtained (2.57 mM, 
[Hb] = 16.6 g/dL, yield 56.1%). 
 
2.7. Size exclusion chromatography (SEC) 
SEC was conducted using an HPLC system (Chromaster; Hitachi High-Technologies 
Corp.) equipped with an SEC column (Shodex Protein KW-804; Showa Denko K.K.) at 
20−29 °C. Effluent was monitored using a diode array detector (5430; Hitachi High-
Technologies Corp.) with absorbance at 419 nm, which corresponds to λmax of the Soret band of 
carbonyl Hb. The modified Hbs solutions were filtered through a syringe-driven filter unit 
(Millex 0.22 μm PVDF filter; Merck Millipore). Then 20 μL of analyte was injected into the 
SEC column through a sampler. PBS was used as an eluent with a 1.0 mL/min flow rate. The 
molecular weight of Hb-rPEG was estimated using a calibration curve obtained using three 
marker kits (MW-GF200 and MW-GF1000; Sigma-Aldrich Corp., and MW-Marker (HPLC); 
Oriental Yeast Co., Ltd., Tokyo, Japan). The molecular weight of the ring-opened polymer was 
estimated by extrapolation of the calibration curve obtained from small linear oligomers, up to 
pentamer, prepared by the reaction of preformed XLHb and mal2-PEG, as described in the 
Results section. 
 
2.8. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
All solutions of Hb derivative were diluted with PBS to the Hb concentration of 0.012 
mM ([Hb] = 0.075 g/dL). Then, each resulting solution was mixed with a half volume of the 
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denaturing buffer31 (0.19 M Tris-HCl pH 6.8, 6.0% (wt/v) SDS, 15% (v/v) 2-mercaptoethanol, 
30% (wt/v) sucrose, and 0.006% (wt/v) bromophenol blue) and was incubated at 80 °C for 15 
min. 
Electrophoresis was performed on a 13% polyacrylamide mini-slab gel using a mini-slab 
electrophoresis system (NA-1010; Nihon Eido Corp., Tokyo, Japan), or on a gradient gel 
(NuPAGE 3-8% Tris-Acetate Protein Gels; Invitrogen Corp., Thermo Fisher Scientific Inc., 
Waltham, U.S.A.) using a mini-slab electrophoresis system (XCell SureLock Mini-Cell; 
Invitrogen Corp., Thermo Fisher Scientific Inc.). An Amersham Low Molecular Weight 
Calibration Kit for SDS Electrophoresis (GE Healthcare Japan Ltd., Tokyo, Japan) and a HiMark 
Pre-Stained Protein Standard (Invitrogen Corp., Thermo Fisher Scientific Inc.) were used for 
molecular weight markers. After the gels were stained with Coomassie brilliant blue, images of 
the stained gels were obtained using transmission scanning (GT-F650; Seiko Epson Corp., 
Nagano, Japan). 
 
2.9. Colloid osmotic pressure (COP) 
COP of the Hb-rPEG was measured using a colloid osmometer (Osmomat 050; Gonotec 
GmbH, Berlin, Germany) with several protein concentrations at 21−24 °C. Albumin, native Hb, 
and XLHb were used as exemplary water-soluble proteins. COP (π) is defined as shown in Eq. 1 
using number-average molecular weights (Mn), the concentration of Hb units (C), the gas 
constant (R), the absolute temperature (T), and the second and the third virial coefficients (A2, 
A3).32 
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𝜋𝜋 =  RT �
𝐶𝐶
 𝑀𝑀n
+ 𝐴𝐴2𝐶𝐶2 + 𝐴𝐴3𝐶𝐶3 + ⋯�                  ⋯ (1) 
Eq. 1 is converted to Eq. 2. 
𝜋𝜋
 𝐶𝐶 
 =  RT �
1 
 𝑀𝑀n
+ 𝐴𝐴2𝐶𝐶 + 𝐴𝐴3𝐶𝐶2 + ⋯�                  ⋯ (2) 
From the intercept (π/C)C➝0 of curve fitting on the plots of π/C versus C, 1/Mn is obtained 
according to Eq. 3. 
1 
 𝑀𝑀n





                 ⋯ (3) 
 
2.10. Dynamic light scattering (DLS) 
The Hb-rPEG particle size distribution was measured using a particle analyzer (ELSZ-
2000ZS; Otsuka Electronics Co. Ltd., Osaka, Japan) equipped with a semiconductor laser (λ = 
660 nm) at 25 °C. The light-scattering signal was detected at 165° (backscatter detection). The 
particle sizes of native Hb and purified XL-poly(Hb−PEG) were measured using a nanoparticle 
size analyzer (SZ-100-S; Horiba, Ltd., Tokyo, Japan) equipped with a 10 mW laser (λ = 532 nm) 
at 25 °C. The light-scattering signal was detected at 173° (backscatter detection). The Hb 
concentration of the Hb-rPEG solution was adjusted to 0.10, 0.50, 1.0, 2.0, and 4.0 g/dL 
(0.015−0.62 mM), and those of native Hb and purified XL-poly(Hb−PEG) solutions were 
adjusted to 0.73 and 0.12 g/dL (0.11 and 0.019 mM), respectively, in PBS (pH 7.4). Before DLS 
measurement, each solution was filtered through a syringe-driven filter unit (Millex 0.22 μm 
PVDF filter; Merck Millipore) to remove dust. 
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2.11. Atomic Force Microscopy (AFM) 
AFM measurement was conducted in liquid following the method reported by Tomita et 
al.33 with some modification (UBE Scientific Analysis Laboratory, Inc., Ube, Japan). A native 
Hb and a XL-poly(Hb−PEG) solutions in PBS were desalted using a centrifugal filter unit (100 
kDa cutoff, Amicon Ultra-15; Merck Millipore) to obtain ca. 0.1 g/dL solution in distilled water. 
Each solution was diluted 103 times with ultrapure water. Then the native Hb and the XL-
poly(Hb−PEG) molecules were fixed on a mica plate. Microscopic images were obtained using 
atomic force microscopy (MultiMode 8; Bruker Corp., Santa Barbara, U.S.A.) with a control 
system (Nanoscope V; Bruker Corp.) using a Si3N4 cantilever. The measurement was conducted 
in ultrapure water at room temperature. The spring constant was 0.7 N/m, and the scanning 
resolution was 512 pixels versus 512 lines.   
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molecule consists of two α (15.1 kDa) and two β (15.9 kDa) subunits. One Hb-rPEG molecule 
consists of two α subunits and one PEG-linked two-β subunit (band a, β−PEG−β, 42.2 kDa). 
 
3.2. Concentration-dependence of Hb-rPEG size by COP and DLS measurements 
The colloid osmotic pressure (COP, π) of Hb-rPEG solution increases with the 
concentration of Hb units (C), similarly to native Hb (Figure 3A). Plots of π/C versus C of Hb-
rPEG showed a parabolic curve (red line), whereas those of some representative water soluble 
proteins, such as human serum albumin (green line), XLHb (purple line), and native Hb (blue 
line), showed linear relations (Figure 3B). The number average molecular weight (Mn) of Hb-
rPEG was found to be 104 kDa from the intercept of the quadric curve fitting (Supporting 
Information Table S1). The value is regarded as reflecting the molecular size in an infinitely 
diluted condition. It almost coincides with that ascertained from SEC analysis (98 kDa). 
Dynamic light scattering (DLS) of Hb-rPEG showed an inconsistent size distribution depending 
on the concentration (Figure 4). The particle diameter of Hb-rPEG was 10.6±3.6 nm at [Hb] = 
0.10 g/dL. It increased with the concentration to reach 20.4±13.7 nm at [Hb] = 4.0 g/dL. The 
polydispersity index also increased with the concentration, indicating that the size distribution 





Products obtained by reacting Hb-rPEG with DBBF at different concentrations of 0.04, 
0.31, and 2.33 mM ([Hb] = 0.25, 2.0, and 15 g/dL) were analyzed using SDS-PAGE (Figure 6). 
Band a of β−PEG−β, one component of Hb-rPEG, disappeared by DBBF crosslinking at 0.04 
mM. Alternatively, a new band b with a lower mobility than band a appeared. The new band b 
was assigned as the PEGylated β−β component with a closed ring structure (β−β−ringPEG), 
which is one component of XL-Hb-rPEG. Both β−PEG−β and β−β−ringPEG are expected to 
have equal molecular weight (42.2 kDa), but because of their different morphologies, they 
showed different mobility in the polyacrylamide gel. In contrast to the diluted condition, a 
polymeric component (poly(β−β−PEG)) was observed as band c by DBBF crosslinking of Hb-
rPEG at a higher concentration of 2.33 mM. When crosslinked at 0.31 mM, both bands b and c 
were observed at almost equal intensity, which supported the SEC result (Figure 5). Free α 
subunits remained after crosslinking at every concentration, indicating that DBBF crosslinks 




The SEC profile of the reaction products of Hb-rPEG and DBBF at Hb concentration of 
10 g/dL (1.55 mM) is shown in Figure 7A. As ring-opening polymerization proceeded, the fixed 
polymer, XL-poly(Hb−PEG), was observed at 6.47 min with 10.9% monomeric XL-Hb-rPEG 
remaining at 10.94 min. The size of the ring-opened product gradually decreased concomitantly 
with increasing concentration of native Hb from 2.0 to 10.0 g/dL (Figures 7B, 7C, and 7D). In 
these chromatograms, discontinuous peaks of a crosslinked dimer, a trimer, a tetramer, and a 
pentamer were observed respectively at ca. 10.0, 9.1, 8.5, and 8.1 min. Monomeric Hbs (Hb-
rPEG and native Hb) were also DBBF crosslinked to generate XL-Hb-rPEG and XLHb, and 
were observed respectively at 10.9 and 11.6 min. No oligomers were found before reacting with 
DBBF (Supporting information Figure S1), indicating that the production of such oligomers 
depends strongly on the concentration, and it is difficult to detect them by SEC without 
crosslinking. 
For comparison, preformed XLHb molecules were conjugated by 1.0 or 0.50 equivalent 
molar mal2-PEG (Figures 7E and 7F). In the case of the 1.0 equivalent molar reaction, 
polymerized XLHb (poly(XLHb)) was observed at 6.45 min, with smaller oligomers (9.20 and 
9.99 min) and unreacted XLHb (11.65 min). In the case of reaction of XLHb with 0.50 
equivalent molar mal2-PEG, the SEC profile of the products (Figure 7F) showed a similar 
profile to that shown in Figure 7D. This result demonstrates that the products of oligomeric 
XLHb obtained by reacting with bi-functional PEG were identical to those of subunit exchange 
between native Hb and Hb-rPEG, followed by DBBF crosslinking. 
Each product observed in Figure 7F at 10.05, 9.18, 8.59, and 8.06 min was fractionated 
and then analyzed again using SEC (Figure 7G). As a reference, the XLHb dimer 
(XLHb−PEG−XLHb) was synthesized by reacting excess XLHb with mal2-PEG (Figure 7H). 
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The profiles of blue chromatograms of Figures 7G and 7H coincided, indicating that the peak at 
10.05 min is ascribable to a dumbbell dimer: XLHb−PEG−XLHb. SDS-PAGE analysis of the 
fractions in Figure 7G clarified that the peak of 9.17 min is a trimer, and those of 8.53 and 8.11 
min are inferred to be a tetramer and a pentamer, respectively (Supporting Information Figure 
S2). 
The relation between the retention time and the molecular weights of these oligomers and 
XLHb is shown as a blue line on a logarithmic scale in Figure 8. They are on a linear fit 
(r2>0.999), and are applicable to produce a calibration curve for XL-poly(Hb−PEG). The green 
line in the figure represents a calibration curve obtained from globular proteins. The slope of the 
green line is steeper than that of the blue line, indicating that PEG moiety provides large 
hydrodynamic volume to the globular proteins. The molecular weights of the ring-opened 
products, XL-poly(Hb−PEG), observed in Figure 5 were estimated by extrapolation of this blue 
line. The molecular weight of XL-poly(Hb−PEG) was controlled in the wide range of 218−812 
kDa by regulating the initial monomer concentration of 0.16−2.33 mM (Supporting information 
Table S3). The molecular weight of XL-poly(Hb−PEG) observed in Figure 7A (6.47 min) was 
estimated as 804 kDa, which corresponded to an undecamer (11 mer). Figures 5, 7A, and 7E 
show that the peak of the polymer appeared abruptly at 6.2 min. The polymer size almost reaches 
the void volume, and it is the detection limit of the column (protein KW804). Therefore, the 





Figure 7. Comparison of SEC profiles of ring-opening and subsequent DBBF crosslinked 
products in the presence of different amount of native Hb (left panels, (A)−(D)), and 
intermolecularly conjugated XLHbs by mal2-PEG (right panels, (E)−(H)). (A) 0 g/dL (no native 

P P
      [P ]   [P ][M]
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𝐾𝐾 ≈  
1 
  [M]e   (𝑛𝑛⋙1)
                 ⋯ (6) 
Hb-rPEG was reacted with DBBF at various initial monomer concentrations ([M]0 = 0.04, 0.08, 
0.16, 0.31, 0.62, 1.55, and 2.33 mM). Then, each solution was diluted to the same concentration 
(0.04 mM). The products were analyzed using SEC as shown in Figure 5. The amount of XL-
Hb-rPEG was quantified from the peak area at 12.91 min (Supporting information Table S4). 
The remaining ratio of cyclic monomer at the equilibrium state is regarded to correspond to that 
of DBBF crosslinked one: XL-Hb-rPEG. Actually, the equilibrium monomer concentration [M]e, 
was obtained from the product of the [M]0 and the remaining ratio of the cyclic monomer. 
The relation between 1/[M]e and [M]0 is presented in Figure 9. The value of 1/[M]e 
declines at a lower [M]0; it becomes constant at a higher [M]0. From the average of 1/[M]e at 
higher concentrations ([M]0 = 0.31, 0.62, 1.55, and 2.33 mM), the K value was found to be 5.68 
mM−1. The corresponding [M]e was 0.176 mM ([Hb] = 1.14 g/dL). From [M]e, the ratio of the 
monomer reacted (P) is defined as Eq. 7. 
𝑃𝑃 =  
 [M]0 − [M]e 
[M]0
                 ⋯ (7) 
The number average degree of polymerization (DP����) defined using P is converted to the ratio of 
[M]0 to [M]e as Eq. 8.36 
DP =  
1
 1 − 𝑃𝑃  = 
 [M]0
  [M]e 
                  ⋯ (8) 
The relation between estimated DP���� and [M]0 is shown in the inset of Figure 9. As shown there,  
DP���� increases proportionally with [M]0. The estimated molecular weight reaches nearly 1 MDa 

 29 
polymer (poly(Hb−PEG)) conjugated through non-covalent intermolecular binding. The α2β2 
tetrameric structures in poly(Hb−PEG) were fixed using DBBF crosslinking. Then the fixed 
polymer XL-poly(Hb−PEG) with the higher molecular weight was fractionated using an open 
column SEC. The SEC profiles and SDS-PAGE images before and after purification are 
presented for comparison in Figure 10. Monomeric structure was observed after DBBF 
crosslinking as a peak at 10.91 min (XL-Hb-rPEG) in chromatogram I, and as bands b 
(β−β−ringPEG) in lanes I. They disappeared after purification (chromatogram II and lane II). 
The retention time of the peak top in Figure 10A becomes shorter by purification from 6.45 to 
6.37 min, indicating the higher molecular weight distribution after purification. The molecular 
weights of XL-poly(Hb−PEG) before and after purification were estimated respectively as 812 
and 844 kDa by extrapolation of the calibration curve in Figure 8. 
The result of 13% SDS-PAGE (Figure 10B, left, lane II) shows that purified XL-
poly(Hb−PEG) consists of free α subunits and polymeric β−β components (poly(β−β−PEG), 
bands d). When we specifically examine the higher molecular weight region in SDS-PAGE 
using a 3−8% gradient gel (Figure 10B, right), bands c and bands d ascribed to poly(β−β−PEG) 
are observed as ladder bands, indicating the discontinuous distribution of molecular weight for 
XL-poly(Hb−PEG). The molecular weight distribution of poly(β−β−PEG) observed as bands d 
in lane II is higher than that of bands c in lane I, which coincides with the SEC result. Bands d 
are observed mainly around the 460 kDa marker, indicating that the molecular weight of the 
corresponding XL-poly(Hb−PEG) is nearly 800 kDa. 
The structure of purified XL-poly(Hb−PEG) was confirmed directly using atomic force 
microscopy (AFM). Hb molecules constituting XL-poly(Hb−PEG) were localized, whereas 
native Hb molecules were dispersed uniformly on the mica plate (Figure 11A). This result 
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indicates the existence of the conjugated Hb polymer. The height of each Hb molecule consisting 
XL-poly(Hb−PEG) was ca. 2−3 nm, which is similar to that of native Hb (Supporting 
information Figure S3). Around 10 Hb molecules were conjugated to form 50−80 nm diameter 
particles. The particle diameter of the purified XL-poly(Hb−PEG) was also estimated as 97±45 





Figure 11. (A) AFM images of native Hb and the purified XL-poly(Hb−PEG) on mica surfaces 
in distilled water, with schematic illustrations of Hb molecules inferred from the AFM images. 
Hb molecules constituting XL-poly(Hb−PEG) were conjugated to form particles of 50−80 nm 
diameter. (B) Particle size distributions of native Hb (blue) and purified XL-poly(Hb-PEG) 




As described herein, we developed an efficient polymerization procedure for creating 
polymerized Hb using a novel approach: ring-opening polymerization. We synthesized a cyclic 
Hb-ring monomer with two β subunits bound through 10 kDa PEG chain (Hb-rPEG, Figure 1). 
During the intermolecular subunit exchange of αβ dimers, Hb-rPEG induces ring-opening 
polymerization to produce a supramolecular Hb polymer: poly(Hb–PEG). The ring-closed 
monomer and the ring-opened polymer were fixed respectively by covalent bonding using DBBF 
crosslinking to obtain XL-Hb-rPEG and XL-poly(Hb–PEG). This is the first example of an Hb 
polymer obtained by ring-opening polymerization and succeeding covalent bonding using site-
specific crosslinking. 
The Hb-ring monomer, Hb-rPEG, was synthesized as shown in Figure 1. A similar 
modification of Hb was reported by Manjula et al. using a shorter 2 kDa bi-functional 
maleimide-PEG (2 kDa mal2-PEG).37 Their purpose was to create an intramolecularly ββ-PEG-
crosslinked-Hb for maintaining allosteric effects of the Hb tetramer.38 As described in their 
report, two equimolar native Hb was reacted to 2 kDa mal2-PEG. Once a dumbbell type Hb 
dimer (Hb–PEG–Hb) is generated, however, it readily transforms to monomeric ββ-PEG-
crosslinked-Hb (with similar structure as Hb-rPEG) and native Hb. Consequently, only a trace 
amount of Hb–PEG–Hb appeared. Acharya et al. reported that a shorter 600 Da mal2-PEG tends 
to generate Hb–PEG–Hb and oligomers through a stepwise reaction, and that of a 2 kDa mal2-
PEG preferentially generates a thermodynamically stable monomeric Hb with a ring structure 
because it has suitable length only for intramolecular binding of two β93Cys thiol groups.39 
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For the work described in this report, a longer 10 kDa mal2-PEG was reacted to a slightly 
excessive amount of native Hb. In the reaction mixture, both Hb-rPEG and dimeric Hb–PEG–
Hb, and their corresponding oligomers were generated because a longer PEG chain enhances the 
exchange of αβ subunits between PEGylated and native Hbs.26 The existence of such oligomers 
was ascertained by DBBF crosslinking of the mixture of Hb-rPEG and native Hb (Figures 7B, 
7C, and 7D). We reported recently that PEGylated Hb is allowed to exchange αβ subunits with 
native Hb.26 Based on this insight, Hb–PEG–Hb is transformed continuously to Hb-rPEG 
through equilibrium by removing native Hb using a salting out technique. The synthesis of Hb-
rPEG and the site-selective PEGylation of two β subunits were confirmed using SEC and SDS-
PAGE (Figure 2). 
The molecular weights of Hb-rPEG determined using SEC (98 kDa) and COP (104 kDa) 
are much larger than expected (75 kDa). Reportedly, conjugated hydrophilic PEG chains expand 
in an aqueous solution and increase the hydrodynamic volume of PEGylated Hb.40 COP (π) is 
described as a function of the concentration of Hb units (C), as shown in Eq. 1. It is converted to 
the equation of π/C as Eq. 2. In general, water-soluble protein shows a linear relation between 
π/C and C, as shown in Figure 3B because the third-order and higher-order virial coefficients in 
Eq. 2 are sufficiently small as to be negligible.32 It is noteworthy that the plots of Hb-rPEG show 
an incontestable parabolic curve (Figure 3B, red line). This result indicates that Hb-rPEG shows 
inconsistent size at every concentration, and indicates that the third virial coefficient A3 is not 
negligible. Actually, the particle diameter increase and dispersity increase depending on the 
concentration were observed in the DLS analysis of Hb-rPEG (Figure 4). These results suggest 
the intermolecular association ascribed to the ring-opening polymerization as shown in Figure 1 
at a higher concentration. Actually, Hb-rPEG can be regarded as the two αβ dimers connected by 
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PEG, induced by dissociation of α2β2 tetrameric structure. The terminal αβ subunits interact 
strongly to form a stable α2β2 tetramer. The interaction functions intramolecularly at a lower 
concentration, and intermolecularly at a higher concentration. Reportedly, the third virial 
coefficient is ascribed to interaction among three molecules.41,42 The intermolecular association 
of two αβ dimers at PEG terminals is inferred to the indispensable third virial coefficient in COP 
measurements of Hb-rPEG. 
Accordingly, Hb-rPEG is regarded as forming a monomeric ring structure by itself. In 
actuality, it also forms a ring-opened polymeric structure (poly(Hb−PEG)), especially at a higher 
concentration. Such behavior is regarded as a ring-chain mechanism of supramolecular 
polymerization.43 Reportedly, some supramolecular protein polymers are constructed using 
specific interactions of proteins such as heme-heme pocket interaction,44 coiled−coil 
interaction,45 helix bundle folding,46 and inter-subunit interaction.47 Our ring-opening 
polymerization technique is the first reported use of the α2β2 tetrameric structure of Hb molecule 
to construct a supramolecular protein polymer.  
In the supramolecular polymers, interactions between monomers are reversible. The 
molecular weight of supramolecular polymer depends on the combination of the monomer 
concentration and the binding constant.1 A few fixation methods have been reported for 
supramolecular polymers of organic compounds using covalent bonding48,49 or mechanical 
interlocking.50 For the present work, the ring-opened and ring-closed structures were fixed by 
DBBF crosslinking, a site-specific covalent bonding of β subunits at a cavity of Hb molecule 
(Figure 1). No example of such a fixing strategy of supramolecular protein polymer employing 
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site-specific covalent bonding of protein subunits has been described in any report of the relevant 
literature. 
By adding DBBF, Hb-rPEG and poly(Hb−PEG) became the corresponding XL-Hb-rPEG 
and XL-poly(Hb−PEG) (Figures 5 and 6). The ratios of crosslinked monomer XL-Hb-rPEG, as 
determined by the peak area in SEC (Figure 5), are regarded as reflecting the ratios of the 
equilibrated state immediately before adding DBBF. Quantitative analysis was done based on the 
ratios of monomeric XL-Hb-rPEG at various initial monomer concentrations [M]0 before DBBF 
crosslinking. The equilibrium monomer concentration [M]e becomes constant at higher [M]0, 
which is the same behavior as the traditional ring-opening polymerization equilibrium of small 
cyclic monomers, as represented by lactones.51 
Equilibrium constant K for Eq. 4 was determined as 5.68 mM−1. Moreover, [M]e was 
0.176 mM ([Hb] = 1.14 g/dL) at a higher polymerization rate (Figure 9). When [M]0 is lower 
than asymptotic [M]e, polymerization is thermodynamically forbidden.52 Hb-rPEG cannot be 
converted into linear macromolecules at a concentration below [M]e (0.176 mM, [Hb] = 1.14 
g/dL), and it starts polymerization above this concentration. Estimated DP���� increased 
proportionally with [M]0. The molecular weight ideally reached nearly 1 MDa (990 kDa) at [M]0 
= 2.33 mM ([Hb] = 15.0 g/dL). This result suggests that the higher concentration of Hb-rPEG 
realizes the higher molecular weight of the ring-opened polymer. However, a limitation of 
solubility exists, as ascribed to the self-volumes of Hbs and PEG chains. Regarding Hb-rPEG 
using 10 kDa PEG, it was difficult to raise the Hb concentration beyond 20 g/dL. 
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The higher molecular weight component of XL-poly(Hb−PEG) was purified and 
characterized. The molecular weight of purified XL-poly(Hb−PEG) obtained by SEC (844 kDa, 
Figure 10A) and that of consisting of polymerized β−β subunits by SDS-PAGE (around 460 
kDa, Figure 10B) show that 11 or more Hb molecules are conjugated by PEG chains. The 
number of conjugated Hb molecules was confirmed directly from the AFM image (Figure 11A). 
In the case of glutaraldehyde-polymerized Hbs (poly-Hbs), which are clinically tested 
HBOCs, the DP���� is almost 2−4 and the maximum number of conjugated Hb units is 6−8.53 
Reportedly, the molecular size of HBOCs is an important factor preventing adverse effects; small 
HBOCs would cause vasoconstriction by extravasation and permeation across the endothelial 
layer.22 Our novel strategy of ring-opening polymerization of Hb realizes higher DP���� compared 
with the poly-Hbs, with notably larger particle diameter (97 nm, Figure 11B) than PEG-
conjugated Hb (13 or 22 nm),10,17 glutaraldehyde-polymerized Hbs (47 nm),17 zero-linked Hbs 
(48 nm),54 and polysaccharide-polymerized Hbs (68 nm).17 
To confirm the polymerization mechanism of Hb-rPEG, native Hb was added as an 
inhibitor before DBBF crosslinking. Results demonstrate that the products become gradually 
smaller with increasing amounts of native Hb. Additionally, discontinuous peaks of small 
oligomers were observed in SEC (Figures 7A−7D), which were identical to oligomeric XLHbs 
conjugated by mal2-PEG (Figures 7F−7H). This result indicates the mechanism clearly. The 
exchange of αβ subunits is the trigger of ring-opening polymerization of Hb-rPEG. Moreover, 
this result indicates that using a chemically modified Hb bearing a functional group as an 
inhibitor makes it possible to provide functional groups at the terminals of XL-poly(Hb−PEG). 
Such terminal-targeted modification would be difficult if using stepwise conjugation of XLHb. 
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Equimolar reaction of XLHb and mal2-PEG produces linear polymer poly(XLHb) by 
alternative conjugation of PEGs and XLHbs (Figure 7E). The poly(XLHb) structure is similar or 
identical to XL-poly(Hb−PEG). Poly(XLHb) is observed at 6.45 min in SEC, which corresponds 
to molecular weight greater than 800 kDa. However, poly(XLHb) contains unreacted XLHb. 
Moreover, the amounts of small oligomers were greater than in XL-poly(Hb−PEG) (Figure 7A). 
The supramolecular polymer (poly(Hb−PEG)) prepared here is regarded as inapplicable 
for blood substitutes because it would decompose to the monomeric structures by dilution in 
blood through the dissociation equilibrium of α2β2 subunits. DBBF crosslinked polymer, XL-
poly(Hb−PEG), is expected to retain the α2β2 structure, which makes it as an injectable fluid. 
Visible light absorption spectrometry of XL-poly(Hb−PEG) showed reversible oxygen binding. 
Its oxygen dissociation curve clarified a higher oxygen affinity (lower P50 value, 5.2 Torr) and a 
smaller Hill number (n = 1.1) than those of native Hb (P50 = 8.2 Torr, n = 2.2) (Supporting 
information Figure S4). Both PEGylation at β93Cys and DBBF crosslinking at β82Lys are 
expected to affect the left shift of the oxygen equilibrium curve.55 Reportedly, HBOCs with a 
high oxygen affinity are effective for targeted oxygen delivery to a hypoxic tissue.56,57 
Consequently, XL-poly(Hb−PEG) will eventually be applicable as other HBOCs with high 
oxygen affinity for such clinical use. 
For other supramolecular protein polymers, multi-level architectures such as microtube,58 
nanolayer,59 nanoparticle, and other three-dimensional structures60 are constructed by the 
combination of self-assembling proteins and artificial scaffolds. Our novel strategy is expected to 
be applicable not only for providing a simple linear Hb polymer but also for constructing other 




In this work, we achieved ring-opening polymerization of Hb triggered by intermolecular 
subunit exchange of αβ dimers. The ring-opened polymer was fixed by covalent bonding with 
intramolecular crosslinking of two β subunits. Analyses of the obtained polymer clarified that 
ring-opening polymerization provides greater benefits for efficiency (DP���� = 13.2 on the average, 
Mn = 990 kDa) compared with random polymerization of Hb using glutaraldehyde. Additionally, 
the amount of lower molecular weight components was found to be smaller than the stepwise 
conjugation of XLHb. This is the first example of ring-opening polymerization using the 
association–dissociation equilibrium of α2β2 subunits in an Hb molecule (α2β2 ⇄ 2αβ), and of 
covalent bonding of the supramolecular Hb polymer using site-specific Hb modification. The 
technique is expected to be applicable not only for providing a simple linear Hb polymer but also 
for constructing other highly ordered Hb architectures, which are expected to realize highly 
aligned and efficiently polymerized Hbs. 
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